Archives

  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br Table br eDemographic and clinico pathological characteristics of patients

    2022-09-13


    Table 1
    eDemographic and clinico-pathological characteristics of patients with known HIV statusa at breast cancer diagnosis.
    Total
    HIV positive
    HIV negative p valueb
    Age at Breast Cancer Diagnosis
    Ethnicity
    Stage at Diagnosis
    Metastasis
    Site of Metastasis
    Tumour grade at diagnosis
    ER status at diagnosis
    PR status at diagnosis
    Her2 status at diagnosis
    Ki67 status at diagnosis
    IHC4 subtype at diagnosis
    a 34 patients (3.2%) had unknown HIV status and were excluded from the analysis.
    b Chi square test or.
    c Mann Whitney test comparing HIV positive to HIV negative proportions for non-missing values.
    e Comparison for positive and negative HER2 values only.
    adjusted for age and ethnicity, tumour stage was not associated with HIV status (Table 2). IHC 4 breast cancer subtype and tumour grade did not differ between HIV positive and HIV negative pa-tients, with or without adjustment for age and ethnicity, except in the unadjusted comparison within subgroups of Luminal B (Table 2).
    Patients with HIV
    HIV status at the time of their breast cancer diagnosis. The duration (median (IQR) of known HIV status prior to breast cancer diagnosis was 4 years. (0e9) years).
    The HIV-infected patients had A23187 median (IQR) CD 4 count of 477 (287e670) cells/mm3 and 59.4% of patients on ARTs had a viral load below detectable levels (i.e. viral load below 50 copies/ml). Among patients with detectable viral loads, the median (IQR) viral load was 4757.5 (268.5e58609.5) copies/ml. The duration of seropositivity and ART use, CD 4 cell count and viral load were not associated with the clinical stage and pathological characteristics of the breast
    Table 2
    Prevalence ratios (PRs) of HIV by breast cancer stage, grade, metastatic disease status, and IHC subtype.
    Unadjusted PR p-value Adjusted PRa p-value Stage at Diagnosis
    Early Stage 1 (Ref)
    No metastasis 1 (Ref)
    a Adjusted for age (linear) and ethnicity (black vs non-black).
    Table 3
    Clinical characteristics of HIV positive patients by time since HIV diagnosis.
    Less than or equal to 1 year More than 1 year P-valuea
    Stage at BC diagnosis
    Metastatic disease
    IHC4 subtypes at diagnosis
    Viral Load
    a Chi square test.
    b Fisher's exact test and.
    c Mann Whitney test comparing duration of HIV positivity.
    Table 4
    Clinical characteristics of HIV positive patients by anti-retroviral (ART) use at breast cancer diagnosis.
    Not on ART
    On ART P-valuea
    Stage at BC diagnosis
    Metastatic disease
    IHC4 subtypes at diagnosis
    #Mann Whitney test comparing use of ART. a Chi square test.
    b Fisher's exact test and.
    Table 5
    Clinical characteristics of HIV positive patients by duration of anti-retroviral therapy (ART) at breast cancer diagnosis.
    Less than or equal to 1 year More than 1 year P-valuea
    Stage at BC diagnosis
    Metastatic disease
    IHC4 subtypes at diagnosis
    #Mann Whitney test comparing duration of ART. a Chi square test.
    b Fisher's exact test and.
    Fig. 1. CD 4 count and HIV viral load. Box and whisker plots of CD 4 cell counts (cells/ mm3) and HIV viral loads (log copies/ml) categorised by duration of HIV seropositivity, use of ARTs and the duration of ART use. Boxes represent interquartile ranges with the median line drawn. Outliers are shown as dots. p-values were calculated using the Mann Whitney test.
    cancer (Tables 3 and 5; Fig. 1). Patients not on ARTs were diagnosed at a later stage than those on ARTs; the difference was of marginal statistical significance (Table 4). Patients neurotransmitters had been diagnosed with HIV more than a year prior to their breast cancer A23187 diagnosis, and those on ART had lower viral loads and higher CD4 cell counts than other patients.